Pharmaceuticals, Biotechnology and Life Sciences
Britain’s biotech sector boasts the strongest new drug pipeline in Europe but industry leaders say it needs continued access to global talent, funding and regulatory clarity to thrive in the future – all of which could be jeopardized by Brexit.
Pharmaceutical companies called on Thursday for a phased transition in drug regulation after Britain leaves the European Union, in order to avoid supply disruption and protect public health.
Europe’s drugmakers pushed for a decision as early as June on the new location for the headquarters of the bloc’s medicines watchdog, which will relocate from London after Britain’s decision to leave the EU.
Novo Nordisk, the world’s top maker of diabetes drugs, is investing 115 million pounds ($145 million) in a new research center in Britain, undeterred by Brexit.